Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts
|
Jul 2016
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
|
Feb 2013
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
|
Mar 2016
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
|
Jan 2014
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
|
Sep 2016
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution
|
Jun 2014
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
|
Sep 2016
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis
|
May 2016
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
|
Apr 2013
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
|
Apr 2014
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|